Valuation: Viking Therapeutics, Inc.

Market Cap 3.16B 2.88B 2.65B 2.41B 4.52B 292B 4.75B 32.26B 12.82B 160B 11.85B 11.6B 501B P/E 2026 *
-4.59x
P/E 2027 * -4.76x
Enterprise Value 2.75B 2.51B 2.31B 2.1B 3.94B 255B 4.14B 28.09B 11.17B 139B 10.32B 10.1B 437B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.17%
Yield 2026 *
-
Yield 2027 * -
1 day-4.14%
1 week-15.23%
Current month-9.20%
1 month-6.10%
3 months-26.91%
6 months-19.26%
Current year-29.59%
1 week 24.67
Extreme 24.67
28.58
1 month 23.82
Extreme 23.82
30.1
Current year 23.82
Extreme 23.82
43.1
1 year 23.82
Extreme 23.82
43.1
3 years 11.54
Extreme 11.545
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 23/09/2012
Director of Finance/CFO 55 03/01/2021
Chief Tech/Sci/R&D Officer 57 10/06/2026
Director TitleAgeSince
Chairman 68 30/04/2015
Chairman 60 23/09/2012
Director/Board Member 53 30/04/2014
Date Insider Type Main position Quantity % Market Cap. Importance
01/08/26 Free

Director

47,133 0.0404%
29/07/26 Sell

Chief Operating Officer

-18,217 0.0157%
29/07/26 Sell

Founder

-148,517 0.1279%
Change 5-day change 1-year change 3-year change Capi.($)
-4.14%-15.23%-27.70%+118.24% 3.16B
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.89B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.65%-2.62%+26.99%+174.31% 40B
Weighted average by Cap. -1.50%-1.96%+31.36%+154.87%

Financials

2026 *2027 *
Net sales - -
Net income -642M -585M -539M -490M -919M -59.44B -966M -6.56B -2.61B -32.47B -2.41B -2.36B -102B -661M -602M -555M -505M -947M -61.23B -995M -6.75B -2.68B -33.44B -2.48B -2.43B -105B
Net Debt -408M -372M -343M -312M -585M -37.81B -615M -4.17B -1.66B -20.65B -1.53B -1.5B -64.81B -431M -392M -362M -329M -617M -39.89B -648M -4.4B -1.75B -21.79B -1.62B -1.58B -68.38B
Projected Income Statement - Annual - Viking Therapeutics, Inc.
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
74
Date Price Change Volume
20/11/26 US$24.77 -4.14% 3,653,951
19/11/26 US$25.84 -1.26% 2,769,997
18/11/26 US$26.17 -2.64% 2,888,048
17/11/26 US$26.88 +0.30% 4,577,483
16/11/26 US$26.80 -8.28% 3,468,902
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Viking Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
24.77USD
Average target price
95.32USD
Spread / Average Target
+284.80%
  1. Stock Market
  2. Stocks
  3. VKTX Stock